Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity

British Journal of Cancer

Volumn 82, Issue 2, 2000, Pages 354-360

  Harding, C ^a   Osundeko, O ^a   Tetlow, L ^a   Faragher, E B ^a   Howell, A ^b   Bundred, N J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Breast

Indexed keywords

ANTIESTROGEN; APOLIPOPROTEIN D; CATHEPSIN D; ESTROGEN; GOSERELIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; ASPIRATION; BREAST CANCER; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MASTALGIA; NIPPLE; PRIORITY JOURNAL; TARGET ORGAN;

EID: 0033978195     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0926     Document Type: Article

References (25)

1. Bergkvist L, Adami HO, Persson I, Hoover R and Schairer C (1989) Risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293-297
2. Brown AMC, Jeltsch JM, Roberts M and Chambon P (1984) Activation of pS2 transcription is a primary response to oestrogen in the human breast cancer cell line MCF7. Proc Natl Acad Sci USA 81: 6344-6348
3. Bulbrook RD, Hayward JL, Wang DY, Thomas BS, Clark GM, Allen DS and Moore JW (1986) Identification of women at high risk of breast cancer. Breast Cancer Res Treat 7: 5-10
4. Cavailles V, Augereau P, Garcia M and Rochefort H (1988) Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin D secreted by breast cancer cells. Nucleic Acids Res 16: 1903-1919
5. Cavailles V, Garcia M and Rochefort H (1989) Regulation of Cathepsin D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol Endocrinol 3: 552-558
6. Chalbos D, Haagensen D, Parish T and Rochefort H (1987) identification and androgen regulation of two proteins released by T47D human breast cancer cells. Cancer Res 47: 2878-2792
7. Early Breast Cancer Trialists Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1-15
8. Ernster VL, Wrensch MR, Petrakis NL, King EB, Miike R, Murai J, Goodson WH III and Siiteri PK (1987) Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens. J Natl Cancer Inst 79: 949-960
9. Haagensen DE, Dilley WG, Mazoujian G and Wells SA (1990) Review of GCDFP-15. Ann NY Acad Sci 586: 161-173
10. Harding C, Howell A and Bundred NJ (1996) Proceedings of the Benign Breast Disease Meeting, July 1995, Parthenon, London
11. Hunt K, Vessey M, Mcpherson K and Coleman M (1987) Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obs Gynecol 94: 620-635
12. Key TJA and Pike MC (1988) The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24: 29-43
13. Lippsett MB and Bergenske DM (1960) Lack of effect of human growth hormone and ovine prolactin on cancer in Man. Cancer Res 20: 1172-1178
14. MacMahon B, Cole P and Brown JB (1986) Urine oestrogens, frequency of ovulation and breast cancer risk: case control study in premenopausal women. J Natl Cancer Inst 77: 613-616
15. Petrakis NL (1986) Physiologic, biochemical and cytological aspects of nipple aspirate fluid. Breast Cancer Res Treat 8: 7-19
16. Petrakis NL, Ernster VL, Sacks ST, King EB, Schweltzer RJ, Hunt TK and King MC (1981) Epidemiology of breast fluid secretion: association with breast risk factors and cerumen type. J Natl Cancer Inst 67: 277-284
17. Petrakis NL, Wrensch MR, Ernster VL, Miike R, Mirai J, Simberg N and Sitteri PK (1987) Influence of pregnancy and lactation on serum and breast fluid oestrogen levels: implications for breast cancer risk. Int J Cancer 40: 587-591
18. Petrakis NL, Lowenstein JM, Wiencke JK, Lee MM, Wrensch MR, King EB, Hilton JF and Miike R (1993) Gross cystic disease fluid protein in nipple aspirates of breast fluid of Asian and non-Asian women. Cancer Epidemiol Biomarkers Prev 2: 573-579
19. Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M and Howell A (1988) The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58: 163-170
20. Rajah TT, Dunn T and Pento JT (1996) The influence of antioestrogens on pS2 and cathepsin D mRNA induction in MCF-7 breast cancer cells. Anticancer Res 16: 837-842
21. Sanchez LM, Visozo F, Diez-Itza I and Lopez-Otin C (1992) Identification of the major protein components in breast secretions from women with benign and malignant breast diseases. Cancer Res 52: 95-100
22. Simard J, Dauvois S, Haagensen D, Levesque C, Merand Y and Labrie F (1990) Regulation of progesterone-binding breast cyst protein GCDFP 24 secretion by oestrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. Endocrinology 126: 3223-3231
23. Weaver I, Christine A, Springer PA and Katzenellenbogen B (1988) Regulation of pS2 gene expression by affinity labelling and reversibly binding oestrogens and antioestrogens. Mol Endocrinol 2: 936-945
24. Wrensch MR, Petrakis NL, Gruenke LD, Ernster VL, Miike R, King EB and Hauck (1990) Factors associated with obtaining nipple aspirate fluid: analysis of 1428 women and literature review. Breast Cancer Res Treat 15: 39-51
25. Zumoff B (1988) Hormonal profiles in women with breast cancer. Anticancer Res 8: 627-636